HSBC Innovation Expects Settled Life Science Market By End Of 2024

Insights From Former SVB Life Science Exec

Michael White, the new UK head of life sciences at HSBC Innovation Banking, made the move from California to join the UK group shortly before Silicon Valley Bank in London collapsed in March 2023. He talks to In Vivo about turbulent life science markets and the future life sciences strategy at HSBC.

Pros and cons concept. Business man with cardboard plus and minus symbol signs.
• Source: Shutterstock

A key component in the European biotech ecosystem, Silicon Valley Bank UK, was saved in March with a buyout by HSBC, Europe’s biggest bank, for just £1 ($1.2).

SVB UK, which had loans of around £5.5bn and deposits of around £6.7bn, was a key lender to the European...

More from Business Strategy

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.